The UK’s Health Secretary, Wes Streeting, has introduced stricter guidelines for the prescription and monitoring of puberty blockers for minors, sparking debate.
While some argue the move is necessary to protect children from potentially irreversible medical interventions, others claim it will harm trans youth by limiting access to healthcare that could alleviate their dysphoria.
The decision follows the findings of the independent Cass Review, which has been criticized by some experts for methodological errors and cherry-picked data.
